These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 8548402

  • 1. Leflunomide, a reversible inhibitor of pyrimidine biosynthesis?
    Zielinski T, Zeitter D, Müller S, Bartlett RR.
    Inflamm Res; 1995 Aug; 44 Suppl 2():S207-8. PubMed ID: 8548402
    [No Abstract] [Full Text] [Related]

  • 2. The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis.
    Cherwinski HM, Cohn RG, Cheung P, Webster DJ, Xu YZ, Caulfield JP, Young JM, Nakano G, Ransom JT.
    J Pharmacol Exp Ther; 1995 Nov; 275(2):1043-9. PubMed ID: 7473131
    [Abstract] [Full Text] [Related]

  • 3. Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans.
    Rückemann K, Fairbanks LD, Carrey EA, Hawrylowicz CM, Richards DF, Kirschbaum B, Simmonds HA.
    J Biol Chem; 1998 Aug 21; 273(34):21682-91. PubMed ID: 9705303
    [Abstract] [Full Text] [Related]

  • 4. Cell cycle regulation and inhibition of de novo pyrimidine biosynthesis by leflunomide.
    Schorlemmer HU, Milbert U, Zeitter D, Haun G, Wunschel M, Bartlett RR.
    Inflamm Res; 1999 Dec 21; 48 Suppl 2():S115-6. PubMed ID: 10667841
    [No Abstract] [Full Text] [Related]

  • 5. In vitro and in vivo effects of leflunomide, brequinar, and cyclosporine on pyrimidine biosynthesis.
    Silva HT, Cao W, Shorthouse RA, Löffler M, Morris RE.
    Transplant Proc; 1997 Dec 21; 29(1-2):1292-3. PubMed ID: 9123312
    [No Abstract] [Full Text] [Related]

  • 6. Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide.
    Greene S, Watanabe K, Braatz-Trulson J, Lou L.
    Biochem Pharmacol; 1995 Sep 07; 50(6):861-7. PubMed ID: 7575649
    [Abstract] [Full Text] [Related]

  • 7. Restriction of de novo pyrimidine biosynthesis inhibits Th1 cell activation and promotes Th2 cell differentiation.
    Dimitrova P, Skapenko A, Herrmann ML, Schleyerbach R, Kalden JR, Schulze-Koops H.
    J Immunol; 2002 Sep 15; 169(6):3392-9. PubMed ID: 12218161
    [Abstract] [Full Text] [Related]

  • 8. Leflunomide interferes with pyrimidine nucleotide biosynthesis.
    Cherwinski HM, Byars N, Ballaron SJ, Nakano GM, Young JM, Ransom JT.
    Inflamm Res; 1995 Aug 15; 44(8):317-22. PubMed ID: 8581517
    [Abstract] [Full Text] [Related]

  • 9. Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide--mechanisms independent of pyrimidine depletion.
    Korn T, Magnus T, Toyka K, Jung S.
    J Leukoc Biol; 2004 Nov 15; 76(5):950-60. PubMed ID: 15328336
    [Abstract] [Full Text] [Related]

  • 10. Effects of leflunomide on hyaluronan synthases (HAS): NF-kappa B-independent suppression of IL-1-induced HAS1 transcription by leflunomide.
    Stuhlmeier KM.
    J Immunol; 2005 Jun 01; 174(11):7376-82. PubMed ID: 15905585
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of smooth muscle cell proliferation in vitro by leflunomide, a new immunosuppressant, is antagonized by uridine.
    Nair RV, Cao W, Morris RE.
    Immunol Lett; 1995 Dec 01; 48(2):77-80. PubMed ID: 8719103
    [Abstract] [Full Text] [Related]

  • 12. Profiles of pyrimidine biosynthesis, salvage and degradation in disks of potato (Solanum tuberosum L.) tubers.
    Katahira R, Ashihara H.
    Planta; 2002 Sep 01; 215(5):821-8. PubMed ID: 12244448
    [Abstract] [Full Text] [Related]

  • 13. Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases.
    Herrmann ML, Schleyerbach R, Kirschbaum BJ.
    Immunopharmacology; 2000 May 01; 47(2-3):273-89. PubMed ID: 10878294
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of smooth muscle cell proliferation in vitro by leflunomide, a new immunosuppressant, is antagonized by uridine.
    Nair RV, Cao W, Morris RE.
    Immunol Lett; 1995 Sep 01; 47(3):171-4. PubMed ID: 8747714
    [Abstract] [Full Text] [Related]

  • 15. Effects of leflunomide and other immunosuppressive agents on T cell proliferation in vitro.
    Chong AS, Rezai K, Gebel HM, Finnegan A, Foster P, Xu X, Williams JW.
    Transplantation; 1996 Jan 15; 61(1):140-5. PubMed ID: 8560553
    [Abstract] [Full Text] [Related]

  • 16. Methotrexate and leflunomide: biochemical basis for combination therapy in the treatment of rheumatoid arthritis.
    Kremer JM.
    Semin Arthritis Rheum; 1999 Aug 15; 29(1):14-26. PubMed ID: 10468411
    [Abstract] [Full Text] [Related]

  • 17. Regulation of B cell function by the immunosuppressive agent leflunomide.
    Siemasko KF, Chong AS, Williams JW, Bremer EG, Finnegan A.
    Transplantation; 1996 Feb 27; 61(4):635-42. PubMed ID: 8610393
    [Abstract] [Full Text] [Related]

  • 18. Biosynthesis and scavenging of pyrimidines by pathogenic mycobacteria.
    Wheeler PR.
    J Gen Microbiol; 1990 Jan 27; 136(1):189-201. PubMed ID: 2191077
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production.
    Siemasko K, Chong AS, Jäck HM, Gong H, Williams JW, Finnegan A.
    J Immunol; 1998 Feb 15; 160(4):1581-8. PubMed ID: 9469413
    [Abstract] [Full Text] [Related]

  • 20. Leflunomide suppresses TNF-induced cellular responses: effects on NF-kappa B, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis.
    Manna SK, Mukhopadhyay A, Aggarwal BB.
    J Immunol; 2000 Nov 15; 165(10):5962-9. PubMed ID: 11067959
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.